×

RNS Number : 7346G

Genedrive PLC

10 August 2016

 

 

RNS Reach

For release: 10 August 2016

 

Genedrive® IL28B Genotyping Assay to be used in STOP-HCV-1 Clinical Trial

 

Genedrive plc (LSE: EHP), the near patient molecular diagnostics company which recently changed its name from Epistem Holdings plc, today announces that its Genedrive® point of care IL28B human genotyping test will be used in the STOP-HCV-1 clinical trial being run by STOP-HCV, a consortium designed to use stratified medicine to optimise the treatment of patients with Hepatitis C Virus infection. The trial is designed to assess the effectiveness of different treatment durations with Direct Acting Antiviral (DAA) treatments on Hepatitis C (HCV) genotype 1 patients (http://www.stop-hcv.ox.ac.uk/stop-hcv-1-trial).

 

Direct Acting Antiviral (DAA) treatments are a new range of drugs which are replacing interferon and other established treatments for HCV. The new DAA treatments regimens are of a shorter duration (12 weeks or less), are well tolerated and offer a much improved chance of cure than earlier treatments. However, costs remain high and, at present, there are no molecular diagnostic tests to predict patients' response to treatment.

 

The STOP-HCV-1 clinical trial will assess two NICE approved DAA treatment combinations and whether the addition of another, older drug (ribavirin) has value in short course treatment. The project is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership. Around 400 patients are expected to be recruited during 2016 and 2017. The aim is to discover which patients may be cured by shorter courses of therapy and how new techniques in molecular diagnostics, including the Genedrive® IL28B point of care test, may be used to predict patient response. Genedrive will provide 20 Genedrive® units and 400 tests for use in the trial.

 

The Genedrive® test produces results within 50 minutes from a simple cheek (buccal) swab compared to the standard approach which uses a blood sample and which can have a service lab return time of 2-3 weeks for results. A recent clinical trial showed the Genedrive® IL28B test was 100% accurate at detecting genetic polymorphisms in HCV patients when compared with the current 'gold-standard' laboratory test.

 

Dr Graham Cooke, Chief Investigator of the STOP-HCV-1 clinical trial, said: "We are pleased to incorporate the Genedrive® IL28B point of care genotyping test in the STOP-HCV-1 clinical trial which aims to identify key markers to guide the duration of treatment required for HCV patients."

 

David Budd, CEO of Genedrive, commented: "The inclusion of our Genedrive® IL28B genotyping test in the STOP-HCV-1 clinical provides further validation of the potential of Genedrive® in point of care genotype diagnostic testing.

 

If the STOP-HCV-1 clinical trial demonstrates that the IL28B genotype is a reliable indication of patient response to shortened DAA treatment, we would anticipate a role for the Genedrive® IL28B test in future HCV treatments. The Genedrive® IL28B  test has been developed alongside the Genedrive® HCV test which is scheduled for market launch in 2017."

 

 

– Ends –

 

 

For further details please contact:

Genedrive plc

David Budd: CEO                                                                                                              +44 (0)161 989 0245

John Rylands: Finance Director

 

Peel Hunt LLP (NOMAD)

James Steel                                                                                                                        +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

 

 

Notes to Editors

 

Genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point-of-need or point-of-care diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

 

Genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.co.uk

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAAKCDQDBKBKFK

Close

×

RNS Number : 3991G

Altitude Group PLC

05 August 2016

 

Altitude Group plc

("Altitude" or the "Group")

Technology Partnership Agreement

 

Altitude Group plc, the provider of innovative technology solutions for small to medium sized businesses, is pleased to announce that its wholly owned subsidiary, Customer Focus Software Inc., has agreed a five-year agreement with Philadelphia, PA based AI Mastermind, a leading buying group serving more than 1,000 promotional product resellers representing over $200 million in annual sales in North America (the "Agreement")

Under the terms of the Agreement, Altitude will provide each AI Mastermind member with an ecommerce website that uses the Group's unique proprietary technology. Altitude will receive a share of the gross margin on all orders that are processed through the platform.

The Agreement is for an initial five-year term, with automatic renewal for a further five years. The Directors expect the first customers to be live by October 2016 and the deal to be earnings enhancing from launch.

Peter Hallett, Non-Executive Chairman of Altitude, said "AI Mastermind is one of  the fastest growing and highly respected buying groups in the $22 billion personalised product industry within the USA. This agreement further validates our decision to focus on sharing of revenue throughput. It gives Altitude access to 1,000 customers for an extremely low acquisition cost, and delivers our unique click to shiptm technology to them instantly."

Jamie Coggeshall, President and AI Mastermind, said, "We are delighted to offer this new solution to our members. We have partnered with Customer Focus on their order management solutions for the last three years and are delighted to now be able to offer this superb new ecommerce website solution that will allow our members easy access to the fastest buying channel. AI Mastermind members already enjoy incredible value for a low monthly fee and they now get the best online shopping experience in the world for no extra charge."

 

 

Enquiries:

Altitude Group plc

Peter J Hallett (Non-Executive Chairman)

Tel: 07887 987469

 

WH Ireland Limited (Nominated Adviser and Broker)

Tim Feather

Liam Gribben

Tel: 0113 394 6600

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCPAMLTMBBMMMF

Close

×

RNS Number : 1377G

APC Technology Group PLC

04 August 2016

 

4th August 2016

APC Technology Group PLC

("APC" or the "Group")

 

APC Technology Group announces Gooee Limited UK launch partnership

APC Technology Group PLC (AIM: APC), the provider of technologies and services intended to help improve organisational sustainability and specialist distributor of electronic components, has signed an agreement to be a UK partner for the launch of the Gooee Internet of Things (IoT) lighting ecosystem.

The Gooee ecosystem provides sensing, control and communication components through a scalable framework that integrates with a cloud platform to connect lighting manufacturers to the IoT.  It significantly increases control, monitoring and data analysis capabilities while driving performance and efficiency improvements.

Under the agreement APC Technology Group PLC will be able to use Gooee's new lighting ecosystem to expand its offering, providing additional functionality and value to customer lighting and IoT solutions.

Richard Hodgson, Chief Executive of APC Technology Group PLC, commented:

"I am delighted to announce our partnership with Gooee. The Gooee system puts lighting at the heart of a building's IoT, providing new opportunities to monitor LED performance, track footfall and communicate directly with occupants.

We believe these factors will be of significant interest to many of our customers, in particular those in the retail, commercial property and industrial sectors, enabling them to operate more efficiently and effectively and ultimately deliver cost savings."

Enquiries:

 

APC Technology Group PLC	01634 290 588
Leonard Seelig, Chairman Richard Hodgson, Chief Executive	www.apc-plc.co.uk
Stockdale Securities Limited (Nominated Advisor and Broker)	020 7601 6100
Mark Brown / Antonio Bossi / Edward Thomas
Redleaf Communications (Financial PR)	020 7382 4730
Rebecca Sanders-Hewett / David Ison / Susie Hudson

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRASSDFSDFMSELA

Close

×

RNS Number : 0565G

Rare Earth Minerals PLC

03 August 2016

 

Rare Earth Minerals Plc

 

("Rare Earth Minerals", "REM" or "the Company")

 

Update on Macarthur Minerals

 

Rare Earth Minerals Plc (AIM: REM; OTC: REMMY)) is pleased to report that Macarthur Minerals ("Macarthur") in which REM owns a 15.5% shareholding, has announced that the majority of its total lithium acreage of 1,489 square kilometres is expected to grant by November / December 2016. The full Macarthur announcement can be found at: http://web.tmxmoney.com/article.php?newsid=8300358548965085&qm_symbol=MMS .

McMahon Mining Title Services Report — Macarthur Minerals Lithium Licences

Macarthur Minerals retains the services of McMahon Mining Title Services ("MMTS") to manage the Company's exploration and mining licences. As detailed in Table 1, MMTS has advised the Company that 13 out of 20 of the Company's Exploration Licence Applications ("Applications") for lithium are expected to grant by November/December 2016.

The grant of exploration licences in Western Australia requires advertisement in accordance with the Mining Act 1978 (WA) ("Mining Act") and subsequent advertisement in accordance with the Native Title Act 1993 (Cth) ("Native Title Act").

All Macarthur Minerals' Applications have been advertised in accordance with the Mining Act and no objections have been maintained. Agreements have been entered into with owners of any overlapping infrastructure leases, where required. An Access Arrangement for Application E46/1115 is currently being finalised.

The majority of Macarthur Minerals' Applications are now progressing through the Native Title Act advertising period, during which, heritage agreements will be entered into with native title parties and provided no objections are raised, are expected to grant in November/December. The remaining Applications will be advertised in the near future.

Until Exploration Licences are granted, the Company will continue prospecting activities to identify exploration targets.

Iron Ore Acreage Update

In addition to Macarthur's lithium acreage, the Company has 15 granted Mining Licences and miscellaneous licences covering 140 square kilometres for its two iron ore projects located North West of Kalgoorlie in Western Australia:

·      Ularring Hematite Project consisting of Indicated 54.46 Mt @ 47.2% Fe and Inferred 25.99Mt @ 45.4% Fe3.

·      Moonshine Magnetite Project consisting of Inferred Mineral Resource consisting of 1,316 Mt @ 30.1% Fe4.

The Company has received approval to develop an iron ore mine for the Ularring Hematite Project and associated infrastructure under the Environmental Protection Act 1986 and the Environmental and Biodiversity Conservation Act 1999. There are no native title claims affecting the iron ore projects.

Table 1 — Lithium Acreage Expected Acreage Grant Timetable

	Tenement		Region		Mining Act Advertised		Native Title Advertised		Expected Grant Date1
	E45/4693		Pilbara		No objection		Yes		November
	E45/4694		Pilbara		Agreement signed		No		TBA
	E45/4702		Pilbara		No objection		Yes		November
	E45/4708		Pilbara		Agreement signed		No		TBA
	E45/4709		Pilbara		No objection		Yes		October
	E45/4710		Pilbara		No objection		Yes		October
	E45/4711		Pilbara		Agreement signed		No		TBA
	E45/4732		Pilbara		No objection		Yes		November
	E45/4735		Pilbara		Agreement signed		No		TBA
	E45/4747		Pilbara		Agreement signed		No		TBA
	E45/4748		Pilbara		Agreement signed		Yes		January
	E45/4749		Pilbara		No objection		Yes		January
	E45/4750		Pilbara		No objection		Yes		December
	E45/4779		Pilbara		Agreement signed		No		TBA
	E46/1114		Pilbara		No objection		Yes		October
	E46/1115		Pilbara		Agreement drafted		No		TBA
	E46/1133		Pilbara		No objection		Yes		November
	E59/2174		Edah		No objection		Yes		October
	E74/0587		Ravensthorpe		No objection		Yes		October
	E74/0588		Ravensthorpe		No objection		Yes		October

ABOUT MACARTHUR MINERALS LIMITED (TSX VENTURE: MMS)

Macarthur Minerals Limited is an exploration and development company that is focused on identifying and developing high grade lithium and counter cyclical investments that complement Macarthur's capabilities.

For further information, please contact:

 

Rare Earth Minerals plc                                                                     +44 (0) 207 440 0647

Andrew Suckling

Kiran Morzaria

 

WH Ireland Limited (Nomad & Broker)                                           +44 (0) 207 220 1666

James Joyce

James Bavister

 

Square1 Consulting                                                                            +44 (0) 207 929 5599

David Bick

Brian Alexander

 

Qualified Person

Kiran Morzaria B.Eng. (ACSM), MBA, has reviewed and approved the information contained in this announcement. Kiran holds a Bachelor of Engineering (Industrial Geology) from the Camborne School of Mines and an MBA (Finance) from CASS Business School.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCKMGGRNZNGVZM

Close

×

The new tax rules apply to dividend payments not interest payments. Therefore tax (currently 20%) continues to be deducted from interest payments from April 2016 onwards where applicable.

Banks and Building Societies may have special arrangements to allow interest to be paid gross.

Close

×

RNS Number : 7626F

Nanoco Group PLC

01 August 2016

 

For immediate release

1 August 2016

 

 

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company") 

 

 

Nanoco and Merck Sign Agreement on

Eco-Friendly Quantum Materials for Displays

 

 

·      Cadmium-free quantum dots enable ultra-bright displays with a substantially extended colour range

·      Nanoco enters into a non-exclusive licence agreement with Merck, which will market Nanoco's material to its broad customer base in the display industry

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, and Merck, a leading science and technology company, today announced the signing of a worldwide material supply and licensing agreement. The licence allows Merck to immediately start marketing Nanoco's cadmium-free quantum dots and to ultimately establish its own production facility to meet growing market demand.

"The agreement is in line with Merck's strategy to sustainably secure its position as the global market and technology leader in display materials. With cadmium-free quantum dots a remarkable increase in the colour range and a significant reduction in power consumption can be achieved. These cadmium-free quantum dots are eco-friendly and also complement our product portfolio for the display industry," said Walter Galinat, member of the Merck Executive Board and CEO of Performance Materials. "The licence agreement with Nanoco will strengthen our position in quantum materials research, for which we laid the foundations by acquiring Qlight Nanotech of Israel last year."

The financial details of the agreement are not being disclosed, but Nanoco will receive a licence fee and royalties on Merck's sales of the Nanoco cadmium-free quantum dots Merck manufactures. In line with Nanoco's commercialisation strategy in the display market, this agreement is non-exclusive. Merck will begin marketing Nanoco's technology in the near term by selling cadmium-free quantum dots manufactured at Nanoco's expanded production plant in Runcorn, UK. The licence allows Merck to establish its own production facility for cadmium-free quantum dots in line with global market demand at a later point in time. Michael Edelman, Nanoco's Chief Executive Officer, added: "This agreement with Merck is another major endorsement of the world-class quality of our cadmium free quantum dot technology. We are convinced that Merck can leverage its position in the display industry with these innovative materials."

Advantages of quantum materials

Quantum materials offer a substantial additional benefit when they are used as color converters in the light source of liquid crystal displays. In conventional displays, the colors blue, green, and red are filtered out of the original white light of the LED light source. A great deal of light is lost in this process. Because a blue LED in combination with red and green quantum materials only generates the blue, green and red light that is perfectly transmitted through the filters, there is much less absorption. This increases the display's brightness, reduces electricity consumption and leads to much purer and potentially stronger colors.

 

This announcement contains inside information.

 

For further information, please contact:

 

Nanoco	Tel: +44 (0) 161 603 7900
Michael Edelman, Chief Executive Officer
David Blain, Chief Financial Officer Caroline Watson, Investor Relations Manager cwatson@nanocotechnologies.com	Tel: + 44 (0) 7799 897357
Canaccord Genuity – Joint Broker	Tel: +44 (0) 20 7523 8000
Simon Bridges Cameron Duncan
Richard Andrews
Liberum – Joint Broker	Tel: +44 (0) 20 3100 2000
Neil Patel
Richard Bootle Steven Tredget
Buchanan	Tel: +44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Stephanie Watson

 

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LC displays, lighting, solar cells and bio-imaging. In the display market, Nanoco has non-exclusive manufacturing and marketing licensing agreements with The Dow Chemical Company and Taiwan's Wah Hong Industrial Corporation. Nanoco also has a strategy of direct sales in display and in its other target markets, including lighting.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Greater China. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

 

 

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

AGRKMGFNGMFGVZZ

Close

×

RNS Number : 1752F

Concepta PLC

26 July 2016

 

26 July 2016

Concepta plc ("Concepta" or the "Company")

Admission to AIM

 

Concepta plc (AIM:CPT), the pioneering UK healthcare company and developer of a proprietary platform and suite of products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility, announces that Admission of its Enlarged Share Capital to trading on AIM has now commenced under the symbol "CPT". SPARK Advisory Partners is acting as Nominated Adviser and Financial Adviser to the Company with Beaufort Capital as Broker.

 

·     Innovative player in the Mobile Health and Connected Health Sector

·     Developed pioneering product 'MyLotus' for home self-testing that helps women with unexplained infertility to conceive

·     MyLotus – only known consumer product to allow both quantitative and qualitative measurement of a woman's personal hCG and LH hormone levels in urine samples to help increase conception rates

·     Defined route to market:

o  Regulatory approvals in place for launch in China – first order from distributor with payment in advance expected after AIM admission

o  CE-Marking for UK and Europe to follow in 2017

·     Significant market opportunity – Chinese and EU infertility market worth c.£600m per annum

·     Management has proven track record in the women's health diagnostics industry

·     New Product Development growth opportunities – proprietary platform lends itself to wider family home-health monitoring to improve individual health parameters including chronic stress, inflammation, urinary tract and healthy pregnancy progression et al.

 

Concepta's AIM Admission follows a reverse takeover from Frontier Resources International plc ("Frontier"), the details of which can be found in the announcement made by Frontier on 25 July 2016 'Result Of General Meetings And Open Offer'.

 

Erik Henau, Chief Executive Officer of Concepta plc said: "We are delighted to be joining AIM at this transformational juncture of our development and believe our listing will significantly enhance our profile and visibility with future customers and partners, as we look to launch our pioneering 'My Lotus' product, targeted at helping women with unexplained infertility to conceive, across key international growth markets.

 

"Unexplained infertility refers to women who have been unable to conceive after six months of trying for a baby. The issue is universal and largely unaffected by demographics, and accounts for 0.36% of the total population in any given market.  Many women within this group often have to wait months or even years before they are eligible for medical intervention which can lead to a long and worrying wait for women and families, not knowing whether or not anything is wrong.  As such, the market opportunity for a 'best in class' product specifically aiming to help women with unexplained infertility to conceive is huge, representing a highly motivated yet neglected group. 

 

"We are expecting a highly active start to our life on AIM, with the roll out of My Lotus in China set to commence in Q3 2016 and thereafter in the UK and Europe in 2017.  In addition, our proprietary platform lends itself to wider family home-health monitoring, and we believe there are exciting growth opportunities for Concepta in the future within the growing global connected healthcare sector set to be worth $61bn by 2020 (PwC).

 

"Finally, the board joins me in welcoming our new and existing shareholders to our register and we now look forward to implementing our defined growth strategy focused on delivering commercial success and becoming the global market leaders for over-the counter products for women with fertility issues."

 

**ENDS**

 

Enquiries:

The Company

Adam Reynolds, Chairman

Tel: +44 (0) 7785 908158

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin/Mark Brady

Tel: +44 (0)20 368 3550

 

Beaufort Securities Limited (Broker)

Jon Belliss

Tel: +44 (0)20 7382 8300

 

Yellow Jersey PR Limited (Financial PR)

Felicity Winkles/ Joe Burgess/ Josh Cole

Tel: +44 (0) 7748 843 871

 

About Concepta Plc:

 

Concepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility*.

 

Founded in 2013, Concepta has developed a revolutionary flagship product 'MyLotus' for home self-testing that helps women with unexplained infertility to conceive.  

 

MyLotus is the only consumer product which allows both quantitative and qualitative measurements of measurement of a woman's personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems.  Competitor products currently only allow qualitative measurement and are based on the 'average woman'.  

 

Concepta has a defined route to market for its new 'My Lotus' product with Regulatory approvals for launch in China in place for 2016 and CE-Marking for UK and Europe to follow in 2017 where the revenue potential of the Chinese and EU infertility market is worth c.£600m per annum for the company.

 

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCPGURUMUPQGQA

Close

×

RNS Number : 0632F

Genedrive PLC

25 July 2016

 

RNS

 

For release: 25 July 2016

 

Genedrive plc ("Genedrive" or the "Company")

 

Re change of name, TIDM and website address

 

 

Genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that further to obtaining shareholder approval on 11 July 2016, Epistem Holdings plc has been renamed Genedrive plc and the Company's TIDM will change to GDR from 08:00 today. The Company's website address has changed to www.genedriveplc.com.

 

The name change follows the Company's recent £6.5m fundraising and reflects Genedrive's focus on the development and commercialisation of its disruptive molecular diagnostic device which targets market opportunities across infectious diseases and patient genotyping.

 

David Budd, CEO of Genedrive, commented: "While the Epistem name was reflective of the heritage of the Company, the change to Genedrive clearly reflects our intention to focus our resources on the global market opportunities in near patient and point of care molecular diagnostics. We have an opportunity to play a significant role in delivering sophisticated diagnostic testing that today millions of people cannot access. We are excited by the future of Genedrive® in bringing the power of hospital-based, central laboratory diagnostics closer to the point of need and the patient setting. Our renewed focus and the recent successful fundraising put us in a strong position to deliver on our diagnostics platform's potential and expand its testing capabilities."

 

The Genedrive® device and tests are designed to bring the power of central laboratory molecular diagnostics to point of care and point of need settings. The Company's tuberculosis/rifampicin resistance (MTB/RIF) test has been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

 

The Company's technology platform has broad applicability and is currently also being applied to diverse targets such as biohazard identification in a $7.8m programme with the US Department of Defense, aquaculture viral identification with the UK Centre for Environment Fisheries and Aquaculture  Science, and has also recently been validated in human genotyping applications.

 

Genedrive continues to provide contract research services to drug development companies under the Epistem brand name.

 

– Ends –

 

For further details please contact:

Genedrive plc

David Budd: CEO                                                                                                              +44 (0)161 989 0245

John Rylands: Finance Director

 

Peel Hunt LLP

James Steel                                                                                                                       +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

 

 

Notes to Editors

 

Genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need or point of care diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

 

Genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.co.uk

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CANDBGDRUUDBGLS

Close

×

RNS Number : 5582E

Pennant International Group PLC

19 July 2016

 

                                                                                     

19 July 2016

Pennant International Group plc (AIM: PEN)

Record Order Book Drives Expansion of Pennant's Business Premises

Pennant International Group plc, ("Pennant" or "the Group"), the AIM quoted supplier of integrated logistic support solutions, products and services, principally to the defence, rail, aerospace and naval sectors and to Government departments, is pleased to announce that in response to the need for additional design, development and production capacity resulting from a record order book and increasing business capabilities, Pennant has taken possession of two commercial premises at Staverton Connection Business Park, Cheltenham.

The new premises, which have a combined floor area of over 8, 000 sq. ft. (743 m2) will almost double Pennant's production capacity to over 20,000 sq. ft. (1,858 m2) and are located a short distance from the Group's existing facilities in Cheltenham.

Work has already commenced fitting out the interiors of the premises, which includes the installation of offices, canteen/kitchen facilities, and mezzanine floors covering 1,600 sq. ft. of workspace. It is expected that the new facilities will be fully operational by the beginning of September.

Commenting on the new facilities, Pennant's Chief Financial Officer, Phil Walker, said: "This long-term investment provides a clear indication of our confidence in the future growth, prosperity and success of the Group."

Enquiries:
Pennant International Group plc	www.pennantplc.co.uk
Phil Walker, CFO	+44 (0) 1452 714 914
Chris Snook, CEO	+44 (0) 1452 714 914
WH Ireland Limited	www.wh-ireland.co.uk
Mike Coe / Ed Allsopp	+44 (0) 117 945 3470
Walbrook PR	www.walbrookpr.com
Paul Vann / Tom Cooper	+44 (0) 117 985 8989 Mob: 07768 807631

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRALIFSEDEIALIR

Close

×

RNS Number : 3785E

Nasstar PLC

18 July 2016

 

Nasstar plc

("Nasstar", "Company" or "Group")

Nasstar rebrand and website Launch

18th July 2016

 

Nasstar (stock code: NASA), a provider of hosted managed and cloud computing services, is pleased to announce the delivery of a key strategic aim for 2016 with the launch of its new website, www.nasstar.com, under a single Nasstar brand with a new look and feel, properly reflecting the size and sophistication of the Group today.

 

Whilst we have now integrated many of the teams, processes and service offerings acquired in the last three years, the Nasstar, e-know.net, Kamanchi and VESK brands have still been going to market under their respective names, causing a level of confusion amongst clients buying services across the Group.

 

The new launch will see all operating divisions consolidate under one Nasstar brand, with investment made into a single fully integrated sales and marketing plan. The aim of the brand consolidation is to maximise the respective strengths of the various offerings within the Group and to help differentiate the full stack of services that the Group can offer, thus ensuring maximum cross sell capabilities and revenue synergy opportunities. We will continue to specialise in selected vertical markets, though we plan to widen the spread, capitalising and building on collective experience and establishing knowledge and expertise in new vertical sectors.

 

The launch of the new brand and web site will see e-know.net Ltd immediately renamed as Nasstar Group Ltd and the www.e-know.net domain being retired and redirected to www.nasstar.com.  Over the coming months, as the new Nasstar brand gets established within the recruitment sector, the Kamanchi Ltd name will change to Nasstar For Recruitment Ltd and the VESK name will be dropped once Nasstar is established within the G-Cloud market place.  Thus within six months the entire group is expected to be operating under the Nasstar brand.

 

For further information, please contact:-

 

Nasstar plc                                                                   +44 (0) 1952 225 000

Nigel Redwood, Chief Executive Officer               

Niki Redwood, Finance Director                          

 

finnCap Limited (Nominated Adviser & Broker)               +44 (0) 20 7220 0500

Julian Blunt, James Thompson (Corporate Finance)

Stephen Norcross (Corporate broking)

 

 

About Nasstar plc

Nasstar (www.nasstar.com) and its wholly owned operating businesses provide hosted managed and cloud computing services that enable subscribers to access their corporate desktop, files, applications, data and email in the Cloud rather than using local server infrastructure. Nasstar specialise in building bespoke cloud hosted services to manage a client's entire application set, tailor made to suit specific industries, designing public, private and hybrid cloud solutions to meet the objectives of the client. The solution is a highly scalable service that provides benefits including anywhere access to computing, a standardised corporate solution that can be accessed globally and in multiple languages and cost savings when compared to the traditional IT ownership model, replacing capital expenditure with a simple usage based payment model.

 

Nasstar (AIM:NASA) was founded in 1998, admitted to AIM in December 2005, acquired e-know.net Limited in a reverse takeover in January 2014, Kamanchi Limited in July 2014 and VESK in October 2015.

 

Ends

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCKMGMNKKZGVZM

Close